X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NYX-458 is an oral small molecule compound that regulates the activity of N-methyl-D-aspartate receptors in the brain. These receptors are essential for nerve cell communication, which occur at structures called synapses located at the junction between nerve cells.
Lead Product(s): NYX-458
Therapeutic Area: Neurology Product Name: NYX-458
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
NYX-783 is a novel, oral, positive allosteric modulator of NMDA receptors in Phase 2b development for the treatment of post-traumatic stress disorder (PTSD) and in Phase 1 development for the treatment of opioid use disorder (OUD).
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $5.6 million Upfront Cash: Undisclosed
Deal Type: Funding November 03, 2022
Details:
NYX-458 is a novel oral NMDA receptor positive allosteric modulator currently in clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
Lead Product(s): NYX-458
Therapeutic Area: Neurology Product Name: NYX-458
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
The poster highlights data from preclinical studies showing that NYX-783, an NMDA receptor positive allosteric modulator, builds long-lasting fear-inhibitory memories in PTSD-relevant models, ultimately leading to reduced spontaneous recovery of fear.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
NYX-783, an NMDA receptor positive allosteric modulator, demonstrates an ability to build long-lasting fear-inhibitory memories in PTSD-relevant models, ultimately leading to a stabilization of fear extinction.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
NYX-783, a novel NMDA receptor positive allosteric modulator signicantly reduced spontaneous recovery of fear in mice in the conventional auditory fear-conditioning model. NYX-783 also reduced spontaneous recovery in the single-prolonged stress model of PTSD.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
NYX-2925, an oral NMDA receptor positive allosteric modulator did not achieve statistically significant separation from placebo on study’s primary endpoint, which assessed change from baseline in average daily pain on numeric rating scale (NRS) during week 12.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The Phase 2b study enrollment completed with 305 patients and, is evaluating the efficacy and safety of NYX-2925, a novel oral NMDA receptor positive allosteric modulator in patients with fibromyalgia.
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
NYX-2925, NMDA receptor positive allosteric modulator currently under evaluation in Phase 2b study in patients with painful DPN and fibromyalgia has also exhibited favorable safety and tolerability profile across a wide dose range in clinical studies.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
